Biotron Limited
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a BITRF research report →
Price Chart
About the company
Biotron Limited is an Australian biotechnology firm dedicated to the creation and market introduction of small molecule therapies designed to combat a range of viral illnesses. Its flagship antiviral compound, BIT225, is currently undergoing Phase II clinical evaluations for addressing infections caused by SARS-CoV-2, HIV-1, and the hepatitis C virus. Established in 1999, the company operates from its main office in Sydney, Australia.
- CEO
- Michelle Miller GCertAppFin
- IPO
- 2013
- Employees
- 3
- HQ
- Sydney, NSW, AU
Get TickerSpark's AI analysis on BITRF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $2.54M
- P/E
- -3.56
- PEG
- 0.01
- P/S
- 0.00
- P/B
- 1.85
- EV/EBITDA
- -0.90
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -54.03%
- ROIC
- -49.02%
Latest fiscal year · YoY change
- Revenue
- $525.87K-71.0%
- Gross Profit
- $525.87K-71.0%
- Op Income
- $-1,556,097
- Net Income
- $-1,516,174-375.9%
- EPS
- $-0.00-133.3%
- OCF Growth
- -213.6%
- FCF Growth
- -211.9%
- 52W High
- $0.04
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.01
- Beta
- -0.64
- RSI (14)
- 49
- Avg Volume
- 9.88K
No earnings-call transcripts are available for BITRF yet.
- Free Float
- 108.5%
- Shares Outstanding
- 906.81M
- Float Shares
- 983.52M
Our BITRF coverage
Recent articles, reports, and earnings notes.
No research on BITRF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate BITRF report →